KALA
KALA BIO, Inc. (NASDAQ)
Healthcare — Biotechnology
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Price History
Fundamentals
| Market Cap | $33.09M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.27 |
| EPS (TTM) | $-102.01 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -238.68% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 41.8 |
| Beta | -2.41 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1030.00 |
| 52-Week Low | $1.62 |
| 50-Day Avg | $3.58 |
| 200-Day Avg | $69.20 |
| Avg Volume | 138.4K |
| Volume | 110.4K |
Performance Analysis
NEUTRALKALA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:16 UTC
Back to Screener Export Report